Management of intrathecal catheter-tip inflammatory masses

A consensus statement

Samuel Hassenbusch, Kim Burchiel, Robert J. Coffey, Michael J. Cousins, Tim Deer, Marc B. Hahn, Stuart Du Pen, Kenneth A Follett, Elliot Krames, James N. Rogers, Oren Sagher, Peter S. Staats, Mark Wallace, Kenneth Dean Willis

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Objectives. In a companion article, we synthesized current clinical and preclinical data to formulate hypotheses about the etiology of drug administration catheter-tip inflammatory masses. In this article, we communicate our recommendations for the detection, treatment, mitigation, and prevention of such masses. Methods. We reviewed published and unpublished case reports and our own experiences to find methods to diagnose and treat catheter-tip inflammatory masses in a manner that minimized adverse neurological sequelae. We also formulated hypotheses about theoretical ways to mitigate, and possibly, prevent the formation of such masses. Results. Human cases have occurred only in patients with chronic pain who received intrathecal opioid drugs, alone or mixed with other drugs, or in patients who received agents that were not labeled for long-term intrathecal use. Most patients had noncancer pain owing to their large representation among the population with implanted pumps. Such patients also had a longer life expectancy and exposure to intrathecal drugs, and they received higher daily doses than patients with cancer pain. Clues to diagnosis included the loss of analgesic drug effects accompanied by new, gradually progressive neurological symptoms and signs. When a mass was diagnosed before it filled the spinal canal or before it caused severe neurological symptoms, open surgery to remove the mass often was not required. Anecdotal reports and the authors' experiences suggest that cessation of drug administration through the affected catheter was followed by shrinkage or disappearance of the mass over a period of 2-5 months. Conclusions. Attentive follow-up and maintenance of an index of suspicion should permit timely diagnosis, minimally invasive treatment, and avoidance of neurological injury from catheter-tip inflammatory masses. Whenever it is feasible, positioning the catheter in the lumbar thecal sac and/or keeping the daily intrathecal opioid dose as low as possible for as long possible may mitigate the seriousness, and perhaps, reduce the incidence of such inflammatory masses.

Original languageEnglish (US)
Pages (from-to)313-323
Number of pages11
JournalPain Medicine
Volume3
Issue number4
DOIs
StatePublished - Dec 1 2002

Fingerprint

Consensus
Catheters
Pharmaceutical Preparations
Opioid Analgesics
Spinal Canal
Life Expectancy
Chronic Pain
Signs and Symptoms
Analgesics
Maintenance
Pain
Incidence
Wounds and Injuries
Therapeutics
Population

Keywords

  • Complications
  • Granuloma
  • Inflammatory mass
  • Intraspinal catheter
  • Intrathecal drugs
  • Morphine
  • Pain

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Hassenbusch, S., Burchiel, K., Coffey, R. J., Cousins, M. J., Deer, T., Hahn, M. B., ... Willis, K. D. (2002). Management of intrathecal catheter-tip inflammatory masses: A consensus statement. Pain Medicine, 3(4), 313-323. https://doi.org/10.1046/j.1526-4637.2002.02055.x

Management of intrathecal catheter-tip inflammatory masses : A consensus statement. / Hassenbusch, Samuel; Burchiel, Kim; Coffey, Robert J.; Cousins, Michael J.; Deer, Tim; Hahn, Marc B.; Du Pen, Stuart; Follett, Kenneth A; Krames, Elliot; Rogers, James N.; Sagher, Oren; Staats, Peter S.; Wallace, Mark; Willis, Kenneth Dean.

In: Pain Medicine, Vol. 3, No. 4, 01.12.2002, p. 313-323.

Research output: Contribution to journalArticle

Hassenbusch, S, Burchiel, K, Coffey, RJ, Cousins, MJ, Deer, T, Hahn, MB, Du Pen, S, Follett, KA, Krames, E, Rogers, JN, Sagher, O, Staats, PS, Wallace, M & Willis, KD 2002, 'Management of intrathecal catheter-tip inflammatory masses: A consensus statement', Pain Medicine, vol. 3, no. 4, pp. 313-323. https://doi.org/10.1046/j.1526-4637.2002.02055.x
Hassenbusch S, Burchiel K, Coffey RJ, Cousins MJ, Deer T, Hahn MB et al. Management of intrathecal catheter-tip inflammatory masses: A consensus statement. Pain Medicine. 2002 Dec 1;3(4):313-323. https://doi.org/10.1046/j.1526-4637.2002.02055.x
Hassenbusch, Samuel ; Burchiel, Kim ; Coffey, Robert J. ; Cousins, Michael J. ; Deer, Tim ; Hahn, Marc B. ; Du Pen, Stuart ; Follett, Kenneth A ; Krames, Elliot ; Rogers, James N. ; Sagher, Oren ; Staats, Peter S. ; Wallace, Mark ; Willis, Kenneth Dean. / Management of intrathecal catheter-tip inflammatory masses : A consensus statement. In: Pain Medicine. 2002 ; Vol. 3, No. 4. pp. 313-323.
@article{30770f2b061e45a39c3b2f3127612b24,
title = "Management of intrathecal catheter-tip inflammatory masses: A consensus statement",
abstract = "Objectives. In a companion article, we synthesized current clinical and preclinical data to formulate hypotheses about the etiology of drug administration catheter-tip inflammatory masses. In this article, we communicate our recommendations for the detection, treatment, mitigation, and prevention of such masses. Methods. We reviewed published and unpublished case reports and our own experiences to find methods to diagnose and treat catheter-tip inflammatory masses in a manner that minimized adverse neurological sequelae. We also formulated hypotheses about theoretical ways to mitigate, and possibly, prevent the formation of such masses. Results. Human cases have occurred only in patients with chronic pain who received intrathecal opioid drugs, alone or mixed with other drugs, or in patients who received agents that were not labeled for long-term intrathecal use. Most patients had noncancer pain owing to their large representation among the population with implanted pumps. Such patients also had a longer life expectancy and exposure to intrathecal drugs, and they received higher daily doses than patients with cancer pain. Clues to diagnosis included the loss of analgesic drug effects accompanied by new, gradually progressive neurological symptoms and signs. When a mass was diagnosed before it filled the spinal canal or before it caused severe neurological symptoms, open surgery to remove the mass often was not required. Anecdotal reports and the authors' experiences suggest that cessation of drug administration through the affected catheter was followed by shrinkage or disappearance of the mass over a period of 2-5 months. Conclusions. Attentive follow-up and maintenance of an index of suspicion should permit timely diagnosis, minimally invasive treatment, and avoidance of neurological injury from catheter-tip inflammatory masses. Whenever it is feasible, positioning the catheter in the lumbar thecal sac and/or keeping the daily intrathecal opioid dose as low as possible for as long possible may mitigate the seriousness, and perhaps, reduce the incidence of such inflammatory masses.",
keywords = "Complications, Granuloma, Inflammatory mass, Intraspinal catheter, Intrathecal drugs, Morphine, Pain",
author = "Samuel Hassenbusch and Kim Burchiel and Coffey, {Robert J.} and Cousins, {Michael J.} and Tim Deer and Hahn, {Marc B.} and {Du Pen}, Stuart and Follett, {Kenneth A} and Elliot Krames and Rogers, {James N.} and Oren Sagher and Staats, {Peter S.} and Mark Wallace and Willis, {Kenneth Dean}",
year = "2002",
month = "12",
day = "1",
doi = "10.1046/j.1526-4637.2002.02055.x",
language = "English (US)",
volume = "3",
pages = "313--323",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Management of intrathecal catheter-tip inflammatory masses

T2 - A consensus statement

AU - Hassenbusch, Samuel

AU - Burchiel, Kim

AU - Coffey, Robert J.

AU - Cousins, Michael J.

AU - Deer, Tim

AU - Hahn, Marc B.

AU - Du Pen, Stuart

AU - Follett, Kenneth A

AU - Krames, Elliot

AU - Rogers, James N.

AU - Sagher, Oren

AU - Staats, Peter S.

AU - Wallace, Mark

AU - Willis, Kenneth Dean

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Objectives. In a companion article, we synthesized current clinical and preclinical data to formulate hypotheses about the etiology of drug administration catheter-tip inflammatory masses. In this article, we communicate our recommendations for the detection, treatment, mitigation, and prevention of such masses. Methods. We reviewed published and unpublished case reports and our own experiences to find methods to diagnose and treat catheter-tip inflammatory masses in a manner that minimized adverse neurological sequelae. We also formulated hypotheses about theoretical ways to mitigate, and possibly, prevent the formation of such masses. Results. Human cases have occurred only in patients with chronic pain who received intrathecal opioid drugs, alone or mixed with other drugs, or in patients who received agents that were not labeled for long-term intrathecal use. Most patients had noncancer pain owing to their large representation among the population with implanted pumps. Such patients also had a longer life expectancy and exposure to intrathecal drugs, and they received higher daily doses than patients with cancer pain. Clues to diagnosis included the loss of analgesic drug effects accompanied by new, gradually progressive neurological symptoms and signs. When a mass was diagnosed before it filled the spinal canal or before it caused severe neurological symptoms, open surgery to remove the mass often was not required. Anecdotal reports and the authors' experiences suggest that cessation of drug administration through the affected catheter was followed by shrinkage or disappearance of the mass over a period of 2-5 months. Conclusions. Attentive follow-up and maintenance of an index of suspicion should permit timely diagnosis, minimally invasive treatment, and avoidance of neurological injury from catheter-tip inflammatory masses. Whenever it is feasible, positioning the catheter in the lumbar thecal sac and/or keeping the daily intrathecal opioid dose as low as possible for as long possible may mitigate the seriousness, and perhaps, reduce the incidence of such inflammatory masses.

AB - Objectives. In a companion article, we synthesized current clinical and preclinical data to formulate hypotheses about the etiology of drug administration catheter-tip inflammatory masses. In this article, we communicate our recommendations for the detection, treatment, mitigation, and prevention of such masses. Methods. We reviewed published and unpublished case reports and our own experiences to find methods to diagnose and treat catheter-tip inflammatory masses in a manner that minimized adverse neurological sequelae. We also formulated hypotheses about theoretical ways to mitigate, and possibly, prevent the formation of such masses. Results. Human cases have occurred only in patients with chronic pain who received intrathecal opioid drugs, alone or mixed with other drugs, or in patients who received agents that were not labeled for long-term intrathecal use. Most patients had noncancer pain owing to their large representation among the population with implanted pumps. Such patients also had a longer life expectancy and exposure to intrathecal drugs, and they received higher daily doses than patients with cancer pain. Clues to diagnosis included the loss of analgesic drug effects accompanied by new, gradually progressive neurological symptoms and signs. When a mass was diagnosed before it filled the spinal canal or before it caused severe neurological symptoms, open surgery to remove the mass often was not required. Anecdotal reports and the authors' experiences suggest that cessation of drug administration through the affected catheter was followed by shrinkage or disappearance of the mass over a period of 2-5 months. Conclusions. Attentive follow-up and maintenance of an index of suspicion should permit timely diagnosis, minimally invasive treatment, and avoidance of neurological injury from catheter-tip inflammatory masses. Whenever it is feasible, positioning the catheter in the lumbar thecal sac and/or keeping the daily intrathecal opioid dose as low as possible for as long possible may mitigate the seriousness, and perhaps, reduce the incidence of such inflammatory masses.

KW - Complications

KW - Granuloma

KW - Inflammatory mass

KW - Intraspinal catheter

KW - Intrathecal drugs

KW - Morphine

KW - Pain

UR - http://www.scopus.com/inward/record.url?scp=0036927372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036927372&partnerID=8YFLogxK

U2 - 10.1046/j.1526-4637.2002.02055.x

DO - 10.1046/j.1526-4637.2002.02055.x

M3 - Article

VL - 3

SP - 313

EP - 323

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 4

ER -